Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourBearish
15 minSymmetric Triangle
5 minBearish
Daily trend turns down below $62.50
Key levels
Resistance$85.65
Resistance$78.58
Support$73.19
Support$70.00
Latest news & SEC filings
No headlines in the last 90 days.
BridgeBio is a commercial-stage biopharmaceutical company focused on treatments for inherited conditions. Its approved products include Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, sold in the U.S. by BridgeBio and elsewhere as Beyonttra through partners such as Bayer in Europe and Alexion in Japan, along with Nulibry for molybdenum cofactor deficiency type A. Its pipeline includes late-stage programs in achondroplasia, a form of muscular dystrophy, and a calcium regulation disorder. It operates across North America, Europe, and Asia.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
SEPT Low Target
$88.00
SEPT Mid Target
$109.00
SEPT High Target
$156.00
Analyst Consensus
$109.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BBIO.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$109.00
32
Moat Score
NONE
2/9
Piotroski Score
-3.5
Altman Z-Score
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
BUYING
2 buys / 1 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Apuli Maricel | officer | Sale | 2,000 | $146K | Oct 30, 2026 |
| Kumar Neil | director officer | Sale | 8,721 | $602K | Sep 17, 2026 |
| Kumar Neil | director officer | Sale | 1,279 | $89K | Sep 17, 2026 |
| Kumar Neil | director officer | Sale | 8,100 | $679K | Aug 19, 2026 |
| Kumar Neil | director officer | Sale | 1,800 | $152K | Aug 19, 2026 |
| Kumar Neil | director officer | Sale | 100 | $9K | Aug 19, 2026 |
| Kumar Neil | director officer | Sale | 1,900 | $154K | Aug 18, 2026 |
| Kumar Neil | director officer | Sale | 17,279 | $1.4M | Aug 18, 2026 |
| Kumar Neil | director officer | Sale | 14,602 | $1.2M | Aug 18, 2026 |
| Kumar Neil | director officer | Sale | 1,199 | $100K | Aug 18, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
126.3%
3yr Revenue CAGR
86.3%
EPS Growth YoY
-31.25%
FCF Growth YoY
14.3%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for BBIO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:31 | $78.17 | 2,537 | $$198K | BUY |
| 21:00:27 | $78.17 | 1,205 | $$94K | BUY |
| 21:00:26 | $78.17 | 1,407 | $$110K | BUY |
| 21:00:25 | $78.17 | 1,529 | $$120K | BUY |
| 21:00:25 | $78.17 | 2,085 | $$163K | BUY |
5 dark pool trades shown · $$685K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for BBIO, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $90 | Dec 18 | 36 | $$625 | 5 | SWEEP |
| CALL | $82.5 | Dec 18 | 36 | $$1810 | 5 | SWEEP |
| CALL | $90 | Dec 18 | 36 | $$254 | 2 | SWEEP |
| CALL | $82.5 | Dec 18 | 36 | $$732 | 2 | SWEEP |
| CALL | $82.5 | Dec 18 | 36 | $$734 | 2 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for BBIO. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $BBIO (BridgeBio Pharma, Inc.) Price: $81.38 | Zone: $81.37 to $93.42 Conviction: HIGH | Analyst upside: +28.3% Near support (0% of range) — reversal watch. Strong positive news (3+ vs...
Join 3,500+ traders discussing BBIO in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for BridgeBio Pharma, Inc. (BBIO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BridgeBio Pharma, Inc. (BBIO) is at $78.17, down 1.72% (-$1.37) at the Nov 12, 2026 close.
The average analyst price target for BBIO is $109.00, ranging from $88 to $156, based on 14 analysts. Latest: Canaccord Genuity maintains on Nov 2, 2026.
Analyst ratings for BBIO: 0 Buy, 36 Hold, 1 Sell — consensus Hold.
BBIO last reported on Oct 29, 2026: EPS -$0.42 vs -$0.54 expected — a beat of 22.6%.
BBIO does not currently pay a dividend.
BridgeBio Pharma, Inc. reported $2.6B of debt and $1.5B of cash (Sep 30, 2026).
Support: $73.19, $70.00, $67.02. Resistance: $78.58, $85.65, $89.49.
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.